Olfr748 is categorized within the vast and diverse family of olfactory receptors, which are integral to the sense of smell in mammals. These receptors belong to the class of G-protein-coupled receptors (GPCRs), characterized by their 7-transmembrane domain structure. The primary function of these receptors, including Olfr748, is to bind specific odorant molecules, leading to a conformational change that activates associated G-proteins. This activation initiates a cascade of intracellular signaling, ultimately resulting in a neuronal response perceived as a smell. Given the lack of specific inhibitors for Olfr748, potential inhibition strategies would be similar to those applicable to GPCRs in general. The inhibition can be direct, targeting the receptor itself, or indirect, influencing the receptor's signaling pathways or regulatory mechanisms. In the case of olfactory receptors, direct inhibition would involve compounds that bind to the receptor in a manner that prevents odorant binding or receptor activation. Such compounds would need to have a high affinity for the receptor and a molecular structure that either competes with the natural odorant ligands or stabilizes the receptor in an inactive conformation.
Indirect inhibition strategies might involve targeting the downstream signaling pathways. For GPCRs, this could include the inhibition of G-protein activation, affecting the production or function of second messengers like cAMP, or modulating the activity of kinases and phosphatases that are part of the receptor's signaling cascade. Additionally, altering the receptor's cellular environment, such as its localization, trafficking, or degradation, could also modulate its function. This type of inhibition requires a deep understanding of the receptor's signaling and regulatory networks, which can be complex and vary significantly among different GPCRs. It's important to note that the development of inhibitors, whether direct or indirect, for a specific olfactory receptor like Olfr748, is challenging due to the high specificity required and the potential for off-target effects. Furthermore, the physiological role and signaling pathways of many olfactory receptors, including Olfr748, are not fully understood, making it difficult to predict the effects of such inhibitors without extensive experimental research. In summary, while theoretical approaches to inhibiting Olfr748 can be proposed based on general GPCR biology, the actual development of such inhibitors requires a detailed understanding of the receptor's structure, function, and interactions within the cell, much of which remains to be elucidated for Olfr748.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $107.00 $316.00 | 3 | |
Cilostazol indirectly inhibits Olfr748 by acting on the cAMP signaling pathway. It inhibits phosphodiesterase III (PDE3), leading to increased cAMP levels, which disrupt the downstream activation of Olfr748, ultimately inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits Olfr748 by targeting the MAPK pathway, a downstream signaling pathway. It specifically inhibits MEK1, disrupting the activation of transcription factors necessary for Olfr748 expression, indirectly inhibiting the gene. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM inhibits Olfr748 by blocking intracellular calcium signaling. It is a cell-permeable calcium chelator that reduces calcium mobilization, leading to decreased sensitivity of Olfr748 to odorant molecules and inhibiting its function. | ||||||
LY 341495 | 201943-63-7 | sc-361244 sc-361244A | 1 mg 10 mg | $87.00 $219.00 | 1 | |
LY341495 acts as an antagonist at metabotropic glutamate receptors, affecting olfactory signal transduction. It leads to reduced activation of Olfr748 and inhibition of its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 interferes with the MAPK pathway, a downstream signaling pathway of Olfr748. By inhibiting MAPK signaling, it disrupts the activation of transcription factors necessary for Olfr748 expression, indirectly inhibiting the gene. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine inhibits Olfr748 by blocking calcium channels, disrupting intracellular calcium signaling. This reduces Olfr748 sensitivity to odorant molecules, ultimately inhibiting its function. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190 inhibits p38 MAPK, a component of the MAPK pathway downstream of Olfr748. This disruption hinders the activation of transcription factors essential for Olfr748 expression, indirectly inhibiting the gene. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits Olfr748 by disrupting intracellular calcium signaling. It specifically targets the endoplasmic reticulum calcium ATPase (SERCA), leading to decreased sensitivity of Olfr748 to odorant molecules and inhibiting its function. | ||||||
MPEP hydrochloride | 96206-92-7 | sc-279454A sc-279454 | 10 mg 50 mg | $133.00 $510.00 | ||
MPEP acts as an antagonist at metabotropic glutamate receptors, affecting olfactory signal transduction. It leads to reduced activation of Olfr748 and inhibition of its function. | ||||||
Nicardipine hydrochloride | 54527-84-3 | sc-202731 sc-202731A | 1 g 5 g | $32.00 $81.00 | 5 | |
Nicardipine inhibits Olfr748 by blocking calcium channels, disrupting intracellular calcium signaling. This reduces Olfr748 sensitivity to odorant molecules, ultimately inhibiting its function. | ||||||